POPULARITY
3 episodes with heor
3 episodes with heor
4 episodes with heor
2 episodes with heor
2 episodes with heor
2 episodes with heor
2 episodes with heor
2 episodes with heor
4 episodes with heor
In this episode, we speak with Silvy Mardiguian, Senior Director and Head of HEOR for Europe & New Markets at BeiGene. Silvy has been co-leading BeiGene's preparedness and organisational readiness for the new Joint Clinical Assessment (JCA) framework, which is going to significantly change the EU HTA landscape.Silvy shares key insights into some of the learnings and challenges she has encountered during this process and highlights why strong cross-functional collaboration has been key to making it all work.We also hear about Silvy's career journey to date — from her move from consulting into industry to the lessons she's picked up along the way. She shares advice for anyone working in value and access, as well as some words of wisdom she'd give her younger self. The opinions shared in this podcast are Silvy's own views. Send us a text
ISPOR 2025, the leading global conference for Health Economics and Outcomes Research (HEOR), takes place 13th-16th May and marks the 30th anniversary of the organisation. Ahead of the event, web editor Nicole Raleigh spoke with Rob Abbott, CEO and executive director of ISPOR – the leading professional society for HEOR globally – about the ins and outs and trends of HEOR. ISPOR's mission is to advance HEOR excellence to improve decision making for health globally, and Abbott explains its focus on the value of particular healthcare interventions, the impact on the quality of life of patients, and how his work is centred around positioning HEOR as a key lever for decision makers and shapers globally to create a world in which healthcare is accessible, effective, efficient, and affordable for everyone. You can listen to episode 177a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.We explore the evolving evidence needs for US payers. Nicole and Bob share unique perspectives around their extensive experience of driving evidence strategies for US pharmaceutical and medical device launches. Additionally, Nicole and Bob share a ‘sneak peek' of exclusive insights from a recent Petauri US payer insights survey conducted to better understand the evidence landscape from the US payers' perspective.They explore:The evolving payer evidence landscape in the USPreferences for clinical and economic evidence by US payersKey differences between the US and other global markets with regard to evidence, HEOR, and market accessOpportunities and challenges when launching new medicines/medical devices/diagnostics in the USInnovative perspectives on evidence planning and strategy for the US marketUS payers' perspectives, with exclusive insights from Petauri Evidence's 2024 US payer surveyThis episode was first broadcast as a live webinar in October 2024. Learn more at: https://mtechaccess.co.uk/navigating-us-payer-evidence-needs/Explore more about launching in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
Rob Abbott, CEO and Executive Director at ISPOR, the Professional Society for Health Economics and Outcomes Research, focuses on defining and measuring value in healthcare, including accessibility, affordability, effectiveness, and patient outcomes. HEOR (health economics and outcomes research) can provide data-driven insights to guide healthcare decision-making, reduce bias in research, and consider a broader range of factors like social determinants of health. This can improve treatment adherence, align therapies with what matters most to patients, and support the evaluation of technology used for treatments and predictive analysis of new therapies. Rob explains, "I'm excited at both the legacy of work that health economics and outcomes research has contributed to, but I'm particularly excited about the extent to which health economics and outcomes research can provide data-driven insights to highlight health interventions that provide the best health outcomes for the investment made. This is good for managing the expenditure of public resources. Still, even more so, data-driven insights can help us lead to better health outcomes, better treatment protocols, and better health outcomes for patients." "As health economists and a professional society representing health economists and outcomes researchers, I think we know that historically, we have defined value quite narrowly in terms of a person's physical health, for instance. But we know that increasingly the concept of whole health or a more holistic approach to health is gaining a lot of traction. So, we are actively engaged in expanding the definition of health to include access to housing, social connections and networks, healthy food and lifestyle choices, and things of that nature. So, I think we are beginning to bring some new ideas to the table in terms of how we think about health." #ISPOR #Patients #Healthcare #DigitalHealth #GlobalHealth #HEOR #RWE #HealthEconomics #HealthAI #DrugPriceNegotiations ISPOR.org Listen to the podcast here
Rob Abbott, CEO and Executive Director at ISPOR, the Professional Society for Health Economics and Outcomes Research, focuses on defining and measuring value in healthcare, including accessibility, affordability, effectiveness, and patient outcomes. HEOR (health economics and outcomes research) can provide data-driven insights to guide healthcare decision-making, reduce bias in research, and consider a broader range of factors like social determinants of health. This can improve treatment adherence, align therapies with what matters most to patients, and support the evaluation of technology used for treatments and predictive analysis of new therapies. Rob explains, "I'm excited at both the legacy of work that health economics and outcomes research has contributed to, but I'm particularly excited about the extent to which health economics and outcomes research can provide data-driven insights to highlight health interventions that provide the best health outcomes for the investment made. This is good for managing the expenditure of public resources. Still, even more so, data-driven insights can help us lead to better health outcomes, better treatment protocols, and better health outcomes for patients." "As health economists and a professional society representing health economists and outcomes researchers, I think we know that historically, we have defined value quite narrowly in terms of a person's physical health, for instance. But we know that increasingly the concept of whole health or a more holistic approach to health is gaining a lot of traction. So, we are actively engaged in expanding the definition of health to include access to housing, social connections and networks, healthy food and lifestyle choices, and things of that nature. So, I think we are beginning to bring some new ideas to the table in terms of how we think about health." #ISPOR #Patients #Healthcare #DigitalHealth #GlobalHealth #HEOR #RWE #HealthEconomics #HealthAI #DrugPriceNegotiations ISPOR.org Download the transcript here
美國的高藥價和高醫療支出世界知名，光是處方藥的支出，就佔了全球處方藥物市場的四成，其中十款藥物在 2022 年佔了 Medicare 將近20%的支出（500 億美元），因此最近被《降低通膨法案》（Inflation Reduction Act, IRA）鎖定，於協商後大砍藥價，有些藥甚至被砍到現在價格的兩折，並於 2026 年實施． 究竟在整條藥物價值鏈當中，有哪些關鍵環節來決定藥價和藥品給付呢？藥品福利管理機構（Pharmacy Benefit Manager, PBM）又在其中扮演什麼樣的角色？美國為什麼不像台灣一樣辦理全民健保呢？關於以上問題，我們很榮幸邀請到目前在 Takeda 藥廠擔任 Reimbursement & Contracting Strategy Lead 的 Mike Lee 來跟我們解析美國藥品錯綜複雜的給付系統，帶我們從更高的視角，一覽美國醫藥產業的運作體系全貌。
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Leqembi, a new biotech drug, has been approved in the UK, but reimbursement may not follow due to concerns about the cost to the NHS. The FDA defended its med device chief's tenure after ethics concerns were raised. Employers are expecting higher health costs next year, driven by rising pharmacy spending on drugs like GLP-1 for obesity. BridgeBio has sent rare disease drugs to a new company called GondolaBio, backed by investors including Viking Global Investors and Sequoia Capital. Versant has launched a new startup called Borealis Biosciences with funding from Novartis.New Jersey has announced plans to erase $100 million in medical debt for nearly 50,000 residents, following similar initiatives by other states and federal regulators. Molina Healthcare has extended CEO Joe Zubretsky's contract through 2027, along with a stock grant potentially worth $51 million. Additionally, CMS has received 12,000 complaints of noncompliance with the No Surprises Act, resulting in $1.7 million in restitution.Novartis and Versant have launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases, following the success of Chinook Therapeutics. Meanwhile, Wuxi Biologics reported a 24% drop in net profit in the first half of 2024 despite signing a record number of new projects. In other news, Biogen and Eisai's Alzheimer's drug Leqvembi has been approved in the UK but deemed too expensive by NICE, while Biomarin has brought on Roche and Amgen alums in an executive restructuring.The text discusses the potential impact of the Democrats' proposed changes to Medicare drug price negotiations on the pharmaceutical industry's research and development (R&D) efforts. Kamala Harris is expected to address these issues during the Democratic National Convention, with the party aiming to lower drug prices by increasing the number of drugs subject to negotiations.TE Connectivity offers sensor solutions for minimally invasive devices, providing precision and safety for procedures such as cardiac mapping and ablation. Their sensor technology can enhance efficacy in heart arrhythmia treatments. The comprehensive sensor solutions guide provides detailed applications, key features, and benefits of their sensors.The text discusses the importance of collecting and using social determinants of health (SDOH) data in health economics and outcomes research (HEOR). It highlights the challenges of collecting SDOH data and provides insights on how to effectively use the data while ensuring privacy and security. The text emphasizes the significance of diverse and inclusive research practices, evaluating data validity and sourcing, and effectively utilizing SDOH data to gain more accurate insights in HEOR.
In this episode we're joined by Joao Carrasco, Director, Global Market Access Team at Bayer Pharmaceuticals. With a 12+ year career spanning both HEOR and Market Access functions, Joao shares his journey and how his strong HEOR background informs his current role. Joao also explores the key pressures and challenges market access teams are facing and his views on the trends shaping the future of market access. The opinions shared in this episode are Joao's own views and not representative of the company he is working for.
In this episode we look at market access through a different lens. We're joined by Becky Germino who has extensive experience in HEOR across a broad range of pharma organisations. Becky joined Sanofi this year as HEVA, Neurology and Immunology Team Leader and explains the key priorities for HEOR teams and their role in working closely with market access to help them define and communicate patient value.The discussion also explores the role of AI for HEOR and market access teams and what's on the horizon that leaders should prepare for. The opinions shared in this episode are Becky's own views.
On this week's episode of The Healthcare Plus Podcast, host Quint Studer is joined by special guest Dr. Riya Pulicharam, a pediatrician by training, certified clinical trials investigator, and co-founder of Caret Health. Over her 20+ year career, Dr. Pulicharam has led more than 500 studies and a number of initiatives focused on reducing total healthcare costs for chronic disease management programs. Dr. Pulicharam shares about her experiences in designing clinical care pathways, particularly for high-risk patients with complex chronic conditions, and emphasizes the need for user-friendly platforms and industry-wide innovation. Dr. Pulicharam also highlights the challenges faced in scaling population health programs to larger organizations and stresses the importance of a centralized approach, advocating for automated data reconciliation and task management. Her ultimate goal is to reduce hospitalizations and emergency room visits while improving patient satisfaction through informed clinical decision-making and by addressing social determinants of health. The discussion underscores the crucial role of data and technology in improving patient care. To learn more about Dr. Riya Pulicharam's population health platform, visit www.CaretHealth.com. About Dr. Riya PulicharamDr. Riya Pulicharam is the co-founder of Caret Health, a clinical execution platform for value-based population health. For more than 20 years, Dr. Pulicharam has served as the National Medical Director for Population Health at Legacy Healthcare Partners (now Optum Care). A pediatrician by training, Dr. Pulicharam was a research fellow at the Department of Obstetrics and Gynecology at Harbor UCLA Medical Center, and later founded the Clinical Research, HEOR, and population health departments for the Legacy Healthcare Partners. Dr. Pulicharam has led more than 500 research studies and is widely recognized as a certified clinical trials investigator.Dr. Pulicharam's primary focus lies in population health, where she addresses social determinants of health and designs clinical care pathways for high-risk patient populations managed within value-based organizations. Notably, her work has been instrumental in various quality improvement initiatives aimed at reducing total healthcare costs for chronic disease management programs, which have been prominently featured in several publications.Driven by a commitment to improving healthcare outcomes, Dr. Pulicharam is currently dedicated to reducing hospitalizations and ER visits for high-risk patients. Her work emphasizes the integration of healthcare technology, automation, and machine learning. Notably, Dr. Pulicharam has invented and patented a groundbreaking population health platform (Caret Health), which achieved a remarkable 57% reduction in hospitalizations and ER visits for high-risk elderly patients with multiple comorbid conditions.
Welcome to this month's episode of Let's Talk Rare: The Life Science Podcast brought to you by Partners4Access. Host Georgie records this episode at the World EPA Conference in Amsterdam. She holds a panel discussion with Juliette Sinclair-Spence, Sandrine Ruiz, Neil Grubert, and Seema Sondhi, and together we shared our experiences at the EPA conference. We also shared our excitement for AI and patient experience topics, as well as the importance of sustainability and finding new pricing approaches in healthcare. Gain insights on inclusivity and involving patients in drug development. Get ready for a meaningful, engaging conversation that will leave you inspired. Take a deep dive into the benefits of tiered pricing, the challenges and concerns of companies and HTA agencies in joint HTA assessments, the importance of inclusivity, and the importance of involving and educating others. Juliette Sinclair-Spence: Bio and Quote LinkedIn Juliette is the Funder and Chairman of the AK Eye Foundation and is a committed
How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market.Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR) about how market access, HEOR and commercialisation leads in Pharma and Medtech can best support overarching product and brand strategy, with a focus on launch challenges in the US market.We take a step back from the intricacies of market access and HEOR, to explore the role our specialism plays in broader commercial and product strategy. We ask: where does market access and HEOR sit in this broader picture, and how can market access teams best support their product and company brand?Using the US market as our case study, we explore:- How to set up your product for success- Commercialisation routes in the US for Pharma and Medtech- The relationship between brand strategy and market access- What Pharma can learn from Medtech's approach to commercialisation- What Medtech innovators can learn from Pharma companies' approach to launchThis episode was first broadcast as a live webinar in January 2024. Learn more at: https://mtechaccess.co.uk/commercialisation-strategy-us-market/Explore our work in the US market: https://mtechaccess.co.uk/launching-healthcare-products-in-the-us/ Discover how Mtech Access can support you global market access and pricing strategy: https://mtechaccess.co.uk/global-market-access-and-pricing/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. ## Strategic consulting firm Lumanity has reorganized and expanded its capabilities to help clients create and demonstrate the value of assets throughout the development and commercialization lifecycle. The company acquired Boston-based life science consultancy Clarion in October 2022, which is now rebranding under Lumanity. In addition, Lumanity is realigning its commercial, medical affairs, and clinical and regulatory strategy teams into a single global strategy consulting capability.This new strategy consulting team will leverage experienced strategists, data luminaries, subject matter experts, and problem solvers to help clients identify and create value inflection points for their assets and organizations. These inflection points occur at critical investment and execution milestones that determine the success of a product in the marketplace.Lumanity's strategy consulting team will draw on its broader capabilities in value demonstration, health economics and outcomes research (HEOR), market access, medical communications, insight, and real-world evidence to provide solutions that support client assets' strategic visions and demonstrate value for stakeholders. The team consists of over 250 consultants based in the US, UK, and EU.The goal of the reorganization is to facilitate the alignment and exchange of expertise across cross-functional teams to improve decision-making and develop innovative solutions with greater impact. By bringing together diverse experts under common leadership, Lumanity aims to provide insights on how to shape assets and organizations for success in future markets.## In other news, pharmaceutical company XYZ has announced positive results from its phase 3 clinical trial for a new cancer treatment. The trial involved over 1,000 patients and showed significant improvement in overall survival rates compared to standard treatments. The company plans to submit the data to regulatory authorities for approval in the coming months.## Moving on, biotech startup ABC has secured $50 million in Series A funding to advance its gene therapy platform. The platform aims to treat rare genetic diseases by delivering therapeutic genes directly into patients' cells. The funding will be used to support further preclinical and clinical development of the platform and expand the company's manufacturing capabilities.## Next up, a new study published in a leading medical journal has found that a combination therapy for Alzheimer's disease showed promising results in early-stage clinical trials. The therapy involves targeting both beta-amyloid plaques and tau protein tangles, which are key pathological features of the disease. The study suggests that this approach may be more effective in slowing down disease progression compared to single-target therapies.## Lastly, a major pharmaceutical company is facing legal challenges over allegations of price-fixing. The company is accused of colluding with other manufacturers to artificially inflate the prices of generic drugs, resulting in higher costs for consumers and healthcare providers. The case is currently under investigation by regulatory authorities, and if found guilty, the company could face significant fines and damage to its reputation.That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more updates on the latest news and developments in the industry.
Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA).We explore:- The nature of the Italian market and the reimbursement process- Pricing and market access considerations when launching in Italy- What the reforms at AIFA mean for market access and managed entry agreements- How the AIFA changes specifically impact innovative products- Changes to early access programmes in Italy- Impact of these changes on international pricing, particularly with the introduction of the EU Joint Clinical Assessment (JCA)This episode was first broadcast as a live webinar in October 2023. Learn more at: https://mtechaccess.co.uk/italy-market-access-aifa-reforms/Subscribe to our newsletter to hear more news, insights and events from Mtech Access.
Join us for this exciting episode of the IPhO Podcast, as we dive into the world of pharmaceutical marketing with Dr. Shivani Vora. As a seasoned professional in the industry, Dr. Vora shares her expertise on global brand marketing, with a specific focus on oncology. Discover Dr. Vora's unique career journey, from her beginnings in HEOR market access to her current role in shaping the future of pharma. Gain valuable perspectives into market access strategies and the challenges of transitioning from a medical to a commercial role. We think you'll enjoy getting to know Dr. Vora as much as we did! And we hope you'll come away with tips to help shape your own future in the world of pharma. Listen now!
Join Rob Matheis and Richard White for a discussion of the basics of what Real World Evidence (RWE) is and how it is different from HEOR, to the big questions of how the global use of RWE has changed over time and how the rise of AI - both analytics and large language models - could change the landscape of RWE. What changes should medical communications professionals be aware of in the reporting and usage of RWE data? Richard White is the Chief Operating Officer of Oxford PharmaGenesis, a global, independent HealthScience communications consultancy. He has more than 20 years of experience in Medical Affairs, and founded the Oxford PharmaGenesis Value Demonstration and Patient Engagement Practices to apply evidence-based communication best practice to clinical, HEOR, RWE, patient-reported outcome (PRO) and patient preference studies. He has run training workshops in these areas for multiple pharmaceutical companies, and has also delivered invited presentations, panel discussions and roundtables at international conferences such as ISMPP, TIPPA, Patient Summit Europe, Patient Engagement & Experience Summit and the World Orphan Drug Congress.
About Jordan Penn:In the past decade, Jordan Penn has spent his healthcare career as a storyteller, leveraging healthcare data and analytics to follow the patient journey, assist in research, and more. His expert knowledge of medical and pharmacy claims, lab data, and EMR/EHR data has made extraordinary contributions to his clients, he has also been deeply involved with analyzing patient journeys to support HEOR studies.At Inovalon, Jordan is a Sr. Principal Sales Engineer, working cross-functionally between sales, product, engineering, marketing, and legal to bring new ideas to existing product offerings. When Jordan is not busy bringing healthcare data to life to inform and improve treatment, he enjoys quality time with his wife and daughter in New Jersey and is an avid weightlifter. Things You'll Learn:DataStream can connect to existing EMRs and is EHR agnostic.DataStream seeks to work with clients who lack or have too much data. DataStream helps customers demystify or declutter what they have to assist providers with the insights they need when treating a patient.The HITECH act incentivized providers and hospitals to adopt electronic health records, increasing from 10% of hospitals in 2008 to over 95% for hospitals and 85% of providers eight years later.The 21st Century Cures Act vouched for interoperability and access to medical patient information without any particular need by the user.DataStream can help doctors have information about their patients on their first visit and help them establish an excellent medical relationship with them. Resources:Connect with and follow Jordan Penn on LinkedIn.Follow Inovalon on LinkedIn.Visit the Inovalon Website.
About The Episode When developing and bringing a therapeutic for a rare disease to market, sponsors should think with the end in mind and plan for payer requirements early in protocol design. The economic and clinical value evidence required by payers for market access differs from the clinical efficacy and safety evidence demanded by regulators. Securing approval but lacking market access results in unrealized revenue and, most importantly, patients left untreated. But how do we price and how do we gain access on the promise of long-term value when we don't have the long-term data? Join Sangeeta Budhia, VP and Global Head, Pricing and Market Access, and Wyatt Gotbetter, Worldwide Head, Access Consulting, of Parexel, to discuss early market access planning, including inclusive data collection, payer models and the impact of new regulations and innovative trial design on data collection and ongoing evidence provision. About the Speakers: Sangeeta Budhia is VP and Global Head, Pricing and Market Access, at Parexel. Her role is to ensure that global strategies including pivotal clinical trials, long-term data collection studies, real world evidence generation plans and HEOR strategies are prepared for the reimbursement challenges that each product will face. Wyatt Gotbetter is SVP & WW Head of Access Consulting, leading all facets of Parexel's Access Consulting business with a focus on helping customers position products for market success. With more than 25 years of industry experience, he brings unique insights to guide Parexel's strategy as we invest in this segment of the business to further our patients-first focus. Sangeeta and Wyatt can be contacted at Sangeeta.Budhia@parexel.com & Wyatt.Gotbetter@parexel.com.
To mark the beginning of Season 5 of the Precision Medicine Podcast, we are honored to welcome Dr. Debra Patt, Executive Vice President of Texas Oncology. As an oncologist and breast cancer specialist at one of the nation's largest community cancer practices, Dr. Patt is on the frontlines of oncology care every day. She joins us to discuss how Texas Oncology uses clinical decision-support technologies and health economics and health services research (HEOR) to deliver more consistent precision oncology care to patients at over 200 locations across Texas. Tune in and subscribe to get the latest episode delivered straight to your in-box.
In this week's episode, Christopher Boone, PhD, VP & Global Head of Health Economic Outcomes and Research (HEOR) at AbbVie, discusses the changing landscape of HEOR, the importance of leadership, collaboration and innovation in the pharmaceutical industry, and the story behind his Twitter handle, DataHippie.
NCODAs Legislative & Policy Liaison, Kevin Scorsone sits down with Debra Patt, MD, PhD, MBA from Texas Oncology and member of NCODAs Legislative & Policy Advisory Committee. As an expert in healthcare policy, Dr. Patt has testified before Congress to protect access to care for Medicare beneficiaries. She chairs the Council on Legislation for the Texas Medical Association and works to formulate responsible healthcare policy that improves the health of Texans. She serves as the Editor in Chief of the Journal of Clinical Oncology Clinical Cancer Informatics, and drives engagement in clinical informatics solutions to enhance healthcare. Her research is in clinical decision support, predictive analytics, telemedicine, HEOR, tools for patient symptom management and quality improvement.
On this week's episode of the PQI Podcast we welcome Dr. Debra Patt, Oncologist with Texas Oncology, Dr. Barry Brooks, Clinical Associate Professor at the University of Texas Health Science Center, and Kevin Scorsone, Legislative & Policy Liaison with NCODA, to discuss the disparities in the oncology space and how legislation can make a major impact moving forward. We also had the opportunity to talk about the new NCODA Oncology State Legislation Tracking Tool. Dr. Patt is an expert in healthcare policy, she has testified before Congress to protect access to care for Medicare beneficiaries. She chairs the Council on Legislation for the Texas Medical Association and works to formulate responsible healthcare policy that improves the health of Texans. She serves as the Editor in Chief of the Journal of Clinical Oncology Clinical Cancer Informatics, and drives engagement in clinical informatics solutions to enhance healthcare. Her research is in clinical decision support, predictive analytics, telemedicine, HEOR, tools for patient symptom management and quality improvement.Dr. Brooks Barry D. Brooks, M.D., is the author of several publications and abstracts. Dr. Brooks is also Vice-Chairman of the Pharmacy and Therapeutics Committee and serves as Chairman of the Contracting Subcommittee for The US Oncology Network. He has been essential in the growth of legislative efforts in the world of oncology and serves on the NCODA Legislative and Policy Advisory Committee.Kevin Scorsone is NCODAs Legislative and Policy Liaison and oversees the efforts of the NCODA Legislative and Policy Advisory Committee. He previously was a Legislative Communications Coordinator for the New York State Assembly and the Manager of Political Engagement for the North Carolina Nurses Association. In addition to his Legislative efforts, Kevin previously ran and worked on various political campaigns on the local, state and federal levels.
jQuery(document).ready(function(){ cab.clickify(); }); Original Podcast with clickable words https://tinyurl.com/ybmuxgdq Contact: irishlingos@gmail.com Anti-war protest in Russia. Agóid frith-chogaidh ar bun sa Rúis. One of the news programs on the Russian television station, 'TV ChannelOne', was interrupted by a protest by anti - war activists in Ukraine. Cuireadh isteach ar cheann de na cláracha nuachta ar an stáisiún teilifíse Rúiseach,'TV ChannelOne' a bhuíochas d'agóid a bhí ar bun ag dream atá in aghaidh na cogaíochta san Úcráin. A sign they had hung up and written in English and Russian said that such a war should not take place, that it should be stopped. Dúradh ar chomhartha a bhí crochta in airde acu agus scríofa i mBéarla agus i Rúisis nár cheart a léithid de chogadh a bheith ann,gur cheart é a stopadh. The Russian public has also been told not to give in to what they say is Russian 'propaganda'. Iarradh freisin ar phobal na Rúise gan géilleadh do 'bholscaireacht' na Rúise mar a deir siad. Protesters said the Kremlin government was clearly 'telling lies to the public' about this war. Dúirt an lucht agóide gur léir go bhfuil an Rialtas sa Kremlin 'ag insint bhréaga don phobal' maidir leis an chogadh seo. This afternoon, the Prime Minister of Russia signed a decree on any export of white and crude sugar from now until 31 August. Tráthnóna inniu, shínigh Príomh-Aire na Rúise foraithne ar aon easportáil de shiúcra bán agus amh-shiúcra as seo go dtí an 31ú Lúnasa. Russia will also not sell the said wheat, rye, barley or maize to states in the Eurasian Economic Union. Ní dhíolfaidh an Rúis ach oiread a dúradh aon chruithneacht,seagal,eorna ná grán buí le stáit atá in Aontas Eacnamíochta na hEoráise. That ban will remain in effect until the said June 30th. Fanfaidh an cosc sin i bhfeidhm a dúradh go dtí an 30Meitheamh.
Episode 303: Bower — Classic Rockers: this is the MT. ROCKMORE for you! If getting ready for the ski road-trips (yes, before snowboards) included listening to Foreigner in your earholes, see how Bower gives them the “rushmore treatment”. SPOILER: No ballads!!
We explore the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe.Orphan medicines and rare disease treatments are faced with a complex, ever-changing market landscape. These treatments also face unique tactical challenges on the route to securing market access.Here we bring together specialists from our global market access (Rob Taaffe), systematic review (Regina Leadley), and health economic (Calum Jones) teams to explore this environment and some of the key hurdles that Pharmaceutical and Medtech innovators need to overcome in order to achieve patient access.Rob, Regina and Calum discuss:Current and future market events and trends for rare disease products across EuropeClinical evidence development, including tactical challenges around evidence generation and how to address theseBuilding the health economic case, including key principles and tactical nuances for health economic modelling in rare and orphan diseaseThis podcast was originally broadcast as a live webinar on 17th November 2021. To learn more and request a copy of the slides used please visit our website.
Pharmacy companies are an important part for Spencer Health Solutions, and pharmacists are an integral part of fulfilling our mission to serve patients in their homes. Hi, I'm Tom Rhodes, CEO, Spencer Health Solutions. We have had the opportunity to bring patient pharmaceutical and digital health thought leaders to previous podcasts. However, today we're speaking with our first pharmacist, digital health advocate and analyst, Timothy Aungst, also known as the digital apothecary. He joins our host Janet Kennedy for an insightful conversation and a call to action to the pharmacy industry on the People Always, Patients Sometimes podcast. Janet Kennedy: (00:45) Welcome to People Always, Patients Sometimes. I'm very excited that today's guest is Timothy Aungst, the digital apothecary. He is an associate professor of pharmacy practice and also a clinical pharmacist. Timothy, welcome to the podcast. Timothy Aungst: (01:03) Thank you, Janet, I'm really excited to be here today to talk about, you know, all this stuff that's been going on. Janet Kennedy: (01:08) It's been a crazy couple of years and that's one of the things that I wanted to talk to you about. I found you because I read your primer, "Digital Health Primer for Pharmacists." You published it in February of 2019. At that time you wrote, "after being involved in the digital health space for almost a decade, I can say with complete sincerity, that the topic is still relatively out of the realm of the general pharmacy profession grasp." Okay. You put a challenge out there. 10 years you've been involved in digital health and you're saying pharmacy is still not up to speed. Would you say that that's true two years later? Timothy Aungst: (01:52) Yes. I still would stand by that. I would argue that we have seen entrepreneurship within the pharmacy profession gravitate towards digital health at large, but I would also conversely say that as a profession for pharmacists, we have not really actually actively engaged in this area. We still lack a large number of educational roles and trying to get people aware of the space. There is a lack of discussion around it. Most of our public organizations that provide guidance on what our next steps for the profession don't really think about it in, I think it's for that reason, I still would say the gap is there. Now that is changing. I would say that there has been a semi call to action amongst several pharmacy organizations, whether it's say PHA, ACP and several others who are now trying to get the profession up to speed on what digital health is. Timothy Aungst: (02:44) And that's been a big focus of mine serving as so-called subject matter expert or key opinion leader to help get information out there regarding the topic. But very, at this time it's quite topical just because we are not actively highly engaged with it. I would probably say we're maybe like two or three years behind other healthcare professions, such as the medical community. The American medical association has an active digital health component that they've been pushing, I would say probably for about two or three years at this point, have reports coming out, organizations associated with it. And I think pharmacists have to play catch up to that. And depending on key stakeholders at this current time that may or may not go fast or may go slow. And that's one thing I'm actively keeping my eye on. Janet Kennedy: (03:27) Well, I'm curious about whether pharmacists or the pharmacy is even included in some of this digital health development. Timothy Aungst: (03:36) I'm always a person who would've actually separate the two. The pharmacist and the pharmacy, I think are no longer synonymous organizations. You don't need a pharmacy to have a pharmacist. I think it's going to be what we see in the 2020s or 2030s at this point. I think those two things will actually diverge and that will just come down to logistics and also some legal parameters I think people are pushing right now. Technicians will be empowered to take on most of the stuff on site and pharmacists will probably feel remote. That being the case then to accomplish that, and also to get pharmacies up to speed where healthcare is going, I think the pharmacy businesses will engage in digital health activities. For good or for bad. The big news right now, right, is that Elizabeth Holmes is in court with Theranos. And if we look at Thernos, who was one of the biggest backers? That was Walgreens. And I always looked at what happened with Walgreens being burned there is a reason why they actually had a huge number of digital health initiatives back in the 2010s. And I think they pulled back because they got burned so heavily. Timothy Aungst: (04:31) In the meantime, we see, let's say a business like CVS Health going down a whole vertical pipeline. Now we got Aetna involved, we got long-term care stuff, we got them pushing to go into kidney disease with dialysis treatments. They are partnering up with digital health companies all over the place. One of the biggest ones, for example, was Sleepio for a digital therapeutic that they've been piloting out there, which has actually initial positive results I'm actually reading through right now. So some of these companies are more involved than others. And I think it's going to come down to, you know, what assets they have to really push that. Whether they see the market going a certain way and they want to meet consumer demands because they are also aware of that, with the changing dynamics within healthcare, pharma is going down the digital health path. Payers are looking at this. Employers are looking at this and even the big tech companies are pushing this stuff out there. So are they going to let other people dictate to them the incumbents of what to do, or are they going to be the drivers themselves? And I think that's going to be something that's going to be interesting to watch. Janet Kennedy: (05:34) Well, so you mentioned the need to separate the pharmacist from pharmacy. So speaking from the individual's perspective, do you hear pharmacists talking about wanting more and better tools to be able to help their patients or are they just basically the Amazon employee at the warehouse where they're just cranking out the work? Timothy Aungst: (05:57) See, I used to think we're still on the razor's edge between two possibilities: one was pharmacists finding some kind of clinical services they pay for under some, say, value-based care agreements. And by providing clinical services would receive renumeration that would allow them to be so-called clinicians in health care. Or the other one was being fully remote and being consigned to these activities, to these virtual workshops where they basically just review medications that have been turned out by Amazon or other companies like true pill, et cetera. There might be a third path, which is a mix between the two. And that's kind of where I'm more leaning towards right now from a pharmacist perspective. Yes, there is a huge interest in digital pathway as a means to basically call back clinical services and kind of like be able to provide services that could then actually have objective feedback in terms of what they did, that they could then bill for services and, you know, make money from it. Timothy Aungst: (06:51) But I don't know if that's going to be enough at this current point to actually say, "oh, well, you're now a remote clinical pharmacist that overviews these data's on people's adherence or their information on disease states, and you get this much," because one of the issues is actually even though they're like remote patient monitoring services that we're seeing CPT codes being pushed up by CMS and such, they're in the physician still. So the pharmacist almost has to still be partnered with someone else in order to receive the renumeration. And then at that point in time, you know, it was kind of like, what slice of the pie are you going to get? And I think that's really what concerns me is that from a healthcare perspective, the pharmacist is still really trapped in their other engagements, which has traditionally held us back. And I think this is because we again have very little stakes in digital health and we were coming to the table kind of late. The other people have already kind of figured this out and have already been making inroads. Making propositions to other organizations to get themselves ahead. And we're kind of almost, I don't want to say asking for crumbs, but we're going to have to really do our best claw back some of this stuff for ourselves. And that's going to delay, I think those aspects. Janet Kennedy: (07:56) And do you see the trade associations being the ones that should be leading this charge? Timothy Aungst: (08:01) I think the trade associations unfortunately all have different stances out why they would want to engage in this stuff. The trade associations value pharmacists to different extents. And within a pharmacy community, we know with the alphabet soup of different pharmacy organizations, they don't all have one central voice. They don't all have one central take on what is the role of pharmacists. I've heard some people say we have a pharmacist practice at the top of their license. I don't know what that means. To be quite honest, whenever I hear that I kind of have to roll my eyes, because what is the top of their license? I think in their eyes probably is just, you know, sending off for prescriptions. So that's great. That's what they see as the business that they have to focus on. I could see definitely some trade associations making an argument to empower technicians, to move back at scale back the role of the pharmacist as a, you know, as a rate limiting step in terms of evaluating prescriptions and getting them out the door. Timothy Aungst: (08:53) And also because there are high cost margin right there, and that would reduce the overhead versus some other trade associations are definitely more clinically focused and would push that down too. So within pharmacy, the unfortunate thing right now is there are some tenuous arguments going on about, you know, who has the right step for the profession or which to be used, how to utilize them. And I think those are the conversations, the hard conversations to have to occur now versus later, because this whole approach of them to let's say digital health and such could become very fragmented. You could see some people that operate large corporations would probably want to use digital health for alternative means versus maybe some smaller companies. And I think that's going to really, for me, I have to bemoan them is that's gonna really muddy the waters and I guess, slow down the process of any adoption by the profession. So yes, I think the trade professions will probably be key here, but I would also, or you, because historically they don't always get along or had the same thought processes that this is going to be another area. That's going to be a sticking point where argue about how to do this. Janet Kennedy: (09:57) You know, I find that health care was still slow to come to digital tools and platforms. I'm curious to know whether, with your ear to the ground, do you find that patients are pushing their desire for digital health into the healthcare system? And do you find that that's being impacted or felt on the pharmacy side? Timothy Aungst: (10:21) And this is a good question because you know, who's the drivers for change. I think it's one of the things that always comes up. Patients are often said to be one of the major drivers, and I do believe that to a certain points payers are probably one of the biggest drivers I would argue though, overall, because they ultimately are paying the money. Patients themselves are vocal population that can dictate those favorable or unfavorable role, lots of different programs and services at the end of the day. So from that perspective, I think with the ongoing pandemic, we saw this huge push for, you know, delivery of services for the ability to have a so-called digital front door. And you know, what was in the news the other day was that Walgreens got in trouble apparently because they're whole vaccine signup and testing site wasn't secure. And the data is now - someone's getting into it. And this, I think is going to give some feedback to people like, you know, if we have to do remote practice, sign up and go through an app or make an account and et cetera, but you can't even keep my data secure - Is that good or bad? Timothy Aungst: (11:17) You know, is that a company I'm going to trust? And those are the things that they're hitting people now it's not so much like, oh, you know, I have a brick and mortar business. People come and buy things and they leave. I just had to worry about the credit cards now I have to worry about their online accounts. I have to worry about health history that's been uploaded or shared. This is definitely a new area I think people are considering. Hospitals and health systems have been dealing with this for years. They've been getting hit by malware attacks for a long time. Now people will ask you for cryptocurrency just to unlock their systems, for goodness sake. And because of this, the population does expect a digital front door, digital services. And I think ultimately businesses have had to pivot to address an answer to that. Timothy Aungst: (11:57) But I don't think they traditionally had that as a, you know, as something that is a high concern for them in the pandemic was a force multiplier that really had to make them rush into, this for good or for bad. I mean, the pandemic is going to go on for awhile. We're going to see this go up in waves, in different parts of the United States. So these companies are going to have a long time to pilot certain programs, but I think many of them have recognized, no matter what, post pandemic, this is going to be a status quo. So whatever works now has to work in the future as well. Janet Kennedy: (12:27) Well, certainly the pandemic has made a lot of things happen faster; that we have seen an acceleration of the interest in some kinds of digital health, particularly tele-health, which sounds new to a lot of people, but it's been around for 20 years. And I know you've been around in the digital health space for over a decade. So let's step back for a second. Could you tell me a little bit about the digital apothecary and why did you start it? Timothy Aungst: (12:54) Sure. So the digital apothecary was kind of like just a little passion product, a little thing that I spread out based on my interests. So I started off as a resident during my PGY1. I got an iPad in 2011. So keep in mind the iPad came out 2010. So one of the things that I did was I actually started processing orders in the hospital using my iPad through Citrix. And this is funny because this is a period where we had so-called COWs, or computers on wheels, or WOWs, workstation on wheels, as they're often called now, and people would argue over these things to process orders in the hospital, et cetera. And I just basically started using my iPad to do all this stuff. And people started catching attention, like why is he doing this stuff faster? He's looking for information faster in there and blah, blah, blah. Timothy Aungst: (13:36) And I was like, yeah, cause I had this device that can do this. I start thinking of something, what is a good app? What is a good thing? And so I started reviewing and looking at stuff and then I joined another group called iMedicalApps and we start reviewing mobile apps. We actually wrote a bunch of papers about how to quantify what is and what is not a good app and to use clinically for patients in patient care. And we gave presentations all over place on this topic. And that was a huge thing for me. And this was when it was mobile health that was my focus. And then circa 2014-15, I moved on to just the bigger digital health space and started writing for different organizations and serving as a speaker advisor consultant for different companies actually were asking a lot of these questions. The years I started thinking with remote patient monitoring, questions about tele-health, pharmacy, how to adopt medication adherence is a big one for me as well. Timothy Aungst: (14:20) And it kind of really changed my thought process in terms of like, you know, this stuff's just kind of adjunctive to care versus, okay, this is going to be actually part in driving care. Eventually digital health, I kinda thought to myself, is just a interim term. I think digital health eventually turns into just health. It's kind of the same period we went through with like digital banking. We don't call it digital banking anymore, we just call it banking. When you go onto your app cash or check or use Venmo, like no one calls it really digital banking. I think that's where healthcare is at. So I noticed there wasn't that many people around the space. There is one person I look up to is Kevin Clawson, who's now into blockchain for healthcare down at Lipscomb. He was a great mentor for me early on. And it was a few other people I've talked to them such as Brent Fox about this too. Timothy Aungst: (15:01) And, but the reality is in the academia circles, that generally there was not a lot of pharmacists, I think, into digital health or into this technology thing. So I kind of got into it, talking about it. I had a lot of people say this was like a waste of time. And I really had to take a thought for myself academically - do I really want to dedicate all my time towards investigating and research in this space. Or should I start moving towards something else as an academic? And I chose to keep on it. And I'm actually pleased because now with the, you know, things are really changing the payment like that, people really want to talk more about it. People aren't real into telehealth. And they were like, who even knows about this in pharmacy? Then my name comes up because that's been something I've been talking about for so long. Timothy Aungst: (15:39) People are looking at different digital health technologies and like, okay, who's in digital talking about, oh, Timothy's talking about it. Timothy's been talking about it for so long now. So it's kind of just in many ways for me, unfortunately, the pandemic has been a driving force around trying to actually get my message out more than it was in the past. I think if the pandemic had not happened digital health would not have seen the rampant advancements that it has, and probably would have been towards the tail end of 2020s that I foresee that would have taken off in versus the early 2020s at this time. Janet Kennedy: (16:09) One of the things you mentioned in your primer was that digital health definitely isn't informatics. Can you tell me what you mean by that? Timothy Aungst: (16:20) Oh, this is, this is, this is a good one. Okay. So this is unbearably one of the hardest questions I had to deal with in terms of talking within my community. So there's always been a push in pharmacy, informatics, you know informational management information, using different data streams and such, EHR management, et cetera, et cetera. And that's been a group that's been around for decades. I would probably say early two thousands, 1990s. We saw them out there and there's always been pharmacy informatics people. And it's the, you know, the American informatics Association and such, or AMIA. But you know, when, when I started talking about digital health, one thing that I actually got in trouble with early on was people like, isn't it just informatics. I was like, what do you mean? Like this is technology. I was like, "technology is not synonymous with informatics." Informatics definitely plays a role in digital health and managing all the data streams that come down. Timothy Aungst: (17:04) But I would argue that the traditional informatics thought processes around management of health. It does not mean lik,e this whole digital health kind of ecosystem. And that's actually where I would have conversations with people like, oh, they'll get all this person, their informatics person, we have the conversation and people will talk about, you know, KPIs, C-Colon and different things in programming. And they'll be like, "Yeah, I don't do any of this stuff. That's not my business. I'm more interested in the clinical workflow design associated with this stuff and how to actually evaluate one technology versus another and blah, blah, blah." And so that does overlap. Yes, it does. But I think some people have assumed that, especially in pharmacy and for pharmacists, that informatics would subsume and take over digital health. And that's one area I'm not too sure on. I think some people may want that. And some people don't. I for one don't. I think informatics works within digital health space in that it's definitely a conversation and there's been other publications around this that kind of delved into a little bit more different therapeutic areas like oncology. But early on, It was very, very difficult actually to separate the two. I think at this time, most of it is separated, but I, that was a early conversation I had had with people. Janet Kennedy: (18:13) Okay. I'm interested in the amount of data that could be available through digital health apps and how a pharmacist might actually interact with that. So I'm really getting around to a conversation about adherence. Right now, when we think of adherence, it's the next fill - did you get the next prescription filled? But there's 30 or even 90 days in between those fills. If you had that data and it was daily, would a pharmacist be able to actually manage that information, and would they want to? Timothy Aungst: (18:48) So here is a loaded question. And I mean this, cause this is an area that I'm fully invested - I love this topic. It is too many stakeholders, I think we can go over in detail about maybe some, the big ones like, you know, who cares about adherence at the end of the day? You know, is it, the patient, is it the clinician, is the payer? I would argue payers recognize there's enough research out there saying that on average, a patient takes for medications, hopefully their diseases won't progress and they'll get better. Same with the clinicians and same with the patients who probably think that to a certain extent. But when we look at adherence data, if we look at HEOR and stuff like that, like what do they use as their metrics? Half the time it's like medication possession ratio, right? And I am not convinced that thing is actually really, really useful. Timothy Aungst: (19:29) I think globally? Yes. I think scalable factor for most organizations, that is the go-to way to doing this. And yet I think about all the patients that I visit in their homes that have boxes of medications still stacked away. And it's like, why are they getting it? Well, you know, I just buy it because I'm told I have to buy it. So you buy your medication and then you store it away, but you're not taking it? And you know, I can't help it go walk away and thinking back my head, like, you know, what? If they show up in a report, people are going to say they're adherent. I just walked into their house and they had like 12 Advair discuses sitting there, and their COPD is still not doing good. Why? No, they're not probably taking and using it correctly, right? But anyone else would probably see that and not make that tie together. Timothy Aungst: (20:10) So I think the biggest problem we've focused and seen in adherence is there's been no way to actually really assess if people have been taking their medications. So we argue about a topic that is potentially anywhere between $300 and $500 billion, which is really, I think, around medication optimization - which adherence is one of those things. But we've had very little quantitative data to back up our arguments. We've had qualitative data; but from a quantitative side, we've never really been able to scale. Even pharma has struggled with this in their clinical trials. You know, we've seen things like MEMSCAP and everything else out there for years trying to make a market here, and they've never really blown up. And then the 2010s, we had a flood in the market of all these different digital health devices because they recognize that stuff, but not all of them have been successful. Timothy Aungst: (20:54) And the question is why? And I think it's because we've come to realize that adherence is very, very, very challenging. Human behavior is very challenging. I think humans are very chaotic in terms of adherence and such. So it comes back to the key stakeholders, you know? Why does the pharmacy care about, you know, adherence? To me, if pharmacy cares about adherence, instead of talking about value for the pharmacy, is the more prescriptions that are dispensed equal more profits. So if a patient's taking their medication on time, theoretically and filling on time, then that profit margin, at least is correct - 12 refills a year for a monthly supply versus if they're not, then they're not refilling and then you're not billing and you're not making money from it. So as a pharmacy, clinicians I think also have kind of a mixed feeling around adherence. To be honest, I think this might be actually one of the biggest conversations that should occur is there are therapeutic areas where we want a hundred percent adherence or at least above 90%. Timothy Aungst: (21:47) There are therapeutic areas where I think we could be fine if people were not truly adherent. If you miss your Metformin a few days a month, am I going to care? Probably not? Your statin, and probably not? You know, and this comes down to, you know, how maybe severe a patient is, you know, how high their co-morbidity is. But there's certain diseases where, you know, what if I miss getting a biologic therapy by a day or two? Is I can really ruin me? Some day, we'll say yes. Some day we'll say no. But there's other therapeutic areas. Like let's say schizophrenia; you know, if they miss your medication, will it be problematic? Yeah. Probably. And the payers are going to be concerned about that. Cause that increases ER visits and hospitalizations, right? So often when we talk about adherence I feel like it's such a global issue that people focus on when it's very granular and it's really around different sensitivities associated with therapeutic areas that I don't really see a lot of people talk about, at large, associate with that technology. Timothy Aungst: (22:40) That technology always seems focused just on trying to solve adherence from a very global perspective. While I think clinically we've had a lot of research talking about adherence from a very small perspective in terms of what diseases and such does it really impact. And so there isn't this mismatch behind there. So there's a financial aspect, there is the clinical aspects I think. And then there's some design aspects, you know, solving adherence, you know? What does it take to do that? And is actually the money invested really worth it? I think it's one thing that's often not discussed like, you know, just because we can solve adherence; should we? And again, they come back to the fact that we blocked a lot of objective information in many ways. If this goes to your question, would we want to actually have this data? Timothy Aungst: (23:21) We are opening Pandora's box. We now know more about people's habits than we have in the past. So to gives some examples would be, let's go with inhalers. Propeller both have this interesting study where they evaluated people's utilization of inhalers and found them, I think they found 60, 80% of people were using their inhaler or Saba rescue inhaler incorrectly. Okay. That's actually really, really concerning, right? Because that's higher than what we probably have historically noted in research. Secondly, if these are patients that we've been signing off saying that they've been adherent or a technique is good, this really calls into question what and how well we've actually been approaching this area for decades. And I think that's actually one of the big things I'm actually concerned about. And I think many companies are kind of thinking about is, you know, we're getting a more objective information about people's habits than we ever had a past. Timothy Aungst: (24:09) And in many ways this could be good, or it could be downright terrible if we're not prepared for the ramifications that everything we thought we knew may be wrong. And I think that's actually an area that most of us may be concerned about because that calls in attention like; okay, we find out that we've been wrong and we've not doing things perfectly. That's great. Well now we've got to fix it. No fix is going to come out overnight. So solving adherence also probably means finding out this data and understanding it while also trying to solve the underlying questions about how do we address some of these issues? Thinking about it clinically, thinking about our workflow. So when pharmacists want to see adherence on a daily basis, I don't think that'd be a problem, but I would throw back then this, what is the value of it? What is the value knowing if someone took their medication on a daily basis? Do they skip through the center pro clinically, is that meaningful? Maybe, maybe not depending on how bad their hypertension is, right? Or maybe heart failure or some other condition? From a peer perspective then maybe yes. And then along with that though, could also be focused on the money that you get for people not refilling on time. So these are the things I think that need to really be questioned. Janet Kennedy: (25:17) Well, it's also the question of the firehose or the very specific stream of data that's relevant. So yes, any digital solution is going to gather all the information, but you wouldn't need all the information. What you would need is the alert that says based on the parameters for this patient, with these meds, now we need to worry about adherence and it could be on day four or five for a lesser impactful drug. It could be on day two for something that is of imperative nature that they take it. So that's the benefit of course, of being overwhelmed by analytics and informatics is that you can also then design the algorithm that sets the actions. Timothy Aungst: (26:02) And that is the biggest issue then at this time, because who decides what the algorithm looks like? And this is a question that I throw most companies. And when I actually hear back, is well do it. But do you actually have the clinical staff and know how to do it? That's the issue. So I'm actually very curious if a company will come along, and actually would build this in their backend. You know, like we already have drug information databases out there, right? You know, is someone going to make something like this that they could then sell out to other companies to then utilize? Are they going to build it in-house, or would these alerts be optionable for a clinical site or a business? That would be nice. But you know, if you gave me a package deal and say, "you know, we could default this or you can change it, whatever you want." Timothy Aungst: (26:46) Then I think that might change the conversation because it's just, you know, how many medications are out there? It's like, you know, NDC codes sitting on the shelf in pharmacies, enormous. So from a theoretical perspective, yes, this could be very possible. For practical perspective, who's going to build it and the timeframe it's going to take to build that is going to be enormous because the fact of matter is we can't build it because we don't know the data around some of this stuff, these questions. And that's the, that's a factor with Pandora's box. It opened up this huge conversation because we have the objective data to back it up now, compared in the past. But we don't know really, you know, what is the right answer? We don't know. If you go through like the literature and start like, you know, going into like pubmed and other things, how many days can you go without skipping his medication? It's not like there's gonna be a publication saying, oh, you can do this, this, this. That stuff doesn't exist, because we've never known. Janet Kennedy: (27:34) All right. Well that sounds like the call to action to the industry, is we've got to start talking about, you know, when you have this data from digital health, how are you going to apply it and make it be not just an endless stream of numbers, but something that is actionable that supports the patient's health journey? Timothy Aungst: (27:53) Actionable data is key. The when to have an action is the unknown. And this is where I think companies could freak out users; because it's easy enough for a patient to call me and say, you know, I've missed my medication past three days, and be like, okay, well you should take your medication or titrate back up, or let's have you in the off spot. And having the patients take that on. All right. Cause they self activated and they chose to do this. I didn't know that until they told me, right? So my liability or whatever we want to call it is limited on a patient discretion, because they own what happened to them. The minute you start putting this subjective information out there, that means the ownership and responsibility shifted to some group that never was responsible in the past. So to expect that people like selling them, want this data and use it, you may hear people say, no, not really. Timothy Aungst: (28:43) And if you peel back the layers, you'll probably eventually find out it's this trepidation around, "I don't know what to do with this data." And I don't really trust the company to tell me what to do with this data, because I don't know where they're pulling that from. So there's gotta be some kind of evidence-based approach around there, but where is the evidence? And then this is where the ground falls out from all of us is, that Aetna says it exists. And that to me, I think is the overwhelming issue around truly objectifying medication here is the fact that we don't know what to do with it this time. And it's very troubling. So for me personally, I think this is great. This is what we should do. Are we there yet? I don't think so. And I think one of the biggest problems has been, it's not the technology. It's not even like the process of logistics; I think it's the overloading clinical scenarios that we never really hadn't think about in the past, and who's going to be responsible for what? Janet Kennedy: (29:37) Okay. You have now laid some pretty big questions that could take us down another rabbit hole for at least an hour. So I'm going to hold those thoughts for our next conversation. And Timothy, just thank you very much for joining us on People Always, Patients Sometimes. Would you mind sharing how they can find you online? Timothy Aungst: (29:58) You can find me on LinkedIn, you can find me on Twitter. Usually just my name. If you look it up, you'll find it. My website, thedigitalapothecary.com is also out there where I write about a lot of stuff. A lot of it is theory crafting, a lot of it is focused on next steps and such or issues I see in the industry. So you're welcome to come and contact me and reach out. Janet Kennedy: (30:17) Excellent. Well, I think we're going to have a part two of this conversation. So I look forward to seeing you on the podcast again soon. Timothy Aungst: (30:24) Thank you very much for having me.
This episode features Yuri Fesko MD, with clinical pathways to help guide diagnosis and treatment in oncology. In this session, Dr Fesko discusses: How clinical pathways can make an impact for hospitals to improve oncology outcomes The critical importance of collaboration for pathologists and oncologists The future of oncology care in integrated health systems Yuri Fesko MD Bio: Dr Yuri Fesko serves as the Executive Medical Director of Medical Affairs at Quest Diagnostics, and the Chief Clinical Officer for Oncology Strategic Collaboration at Quest. Born and raised in New York City, Dr Fesko trained at Case Western Reserve University, and completed his fellowship at University Hospitals of Cleveland. After his fellowship, Dr Fesko served as the Chief of Community Oncology for Wake County through Duke University Health System.An experienced oncologist and medical business leader, he is currently responsible for strategic clinical development at Quest across multiple functional areas including Regulatory FDA, HEOR, and R&D. ----more---- ------------------------------ Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve healthcare management. Quest Diagnostics annually serves 1 in 3 adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.
Part two in the series of MAPS HEOR Podcasts sponsored by the AlphaGroup of Medical Communication Companies. This Podcast features Dr. Kent Summers and Dr. Steve Camper discussing the collaboration of Medical Affairs teams with Health Economics and Outcomes Research.
Getting a drug product into the hands of patients is not a simple task. What was once a straightforward “back office” operation has, with the advent of oncology, rare disease and other kinds of specialty therapeutics, risen to a level of complexity that requires greater strategy, planning and logistics acumen than ever before. Tony Lanzone, Managing Director, Value, Access and HEOR at Syneos Health provides a deep dive into the art and science of getting therapies from the manufacturer to the patient, and how the right trade and distribution strategy can provide a true competitive advantage.If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.
在新藥上市前後有一系列的準備工作，這集就來為大家介紹健康經濟與療效研究（HEOR）部門如何利用設計實驗和分析 real world data（真實世界數據），在藥品上市前、中、後期與各國的法規部門和保險公司互動所扮演的重要角色。 分段重點： (1:28) 探索career path: dry lab / wet lab / 臨床藥師 / 藥物經濟學 (3:30) Health Administrative Program學些什麼? (4:55) 畢業後的選項 (6:11) HEOR consulting / CRO 的工作內容 (6:53) 轉換跑道進入藥廠的原因 (9:20) 藥品上市和保險公司的關係 (13:08) 什麼是HEOR (Health Economics and Outcome Research)? (18:50) 競爭產品出現了怎麼辦? (22:10) Real World Data的來源? (26:48) HEOR部門的架構 (30:23) 藥價制定 (32:52) 進入HEOR的所需背景知識與技能 (36:53) 十年前，十年後 (42:22) 職涯規劃上如何把握升職機會 (46:00) 求職路上 歡迎來信：tmrbiotech.moments@gmail.com
MAPS speaks with Kent Summers, HEOR Lead at AlphaGroup and Steve Camper, VP of Medical Affairs at Blue Earth Diagnostics, about building Health Economics and Outcomes Research capabilities within Medical Affairs.
MINISERIES ALERT - DAY 8 of the 12 Days of Education - our final miniseries for Season 3 of The Edutainer has arrived - just in time for the holidays! We're counting down 12 certificates/certifications/prof. designations found on our 2021 Tracker of Healthcare Certificates & Certifications and our Bundled Live Webinar on 12/19! Hurry and register at: https://payhip.com/b/Cf0Z Definitions What's the difference between a certification and a certificate, anyway? Today, we have the Tufts HEOR Certificate! https://www.tuftsctsi.org/education/clinical-and-translational-science-graduate-program/health-economics-and-outcomes-research-heor-certificate-program/ Also - here's the chat I had with Erin Z. on HEOR and HECON for career development: https://podcasts.apple.com/us/podcast/health-economics-outcomes-research-what-can-pharmacists/id1355247028?i=1000460050548 ___ Day 1 - Ground definitions & CPBS Day 2 - CPXP Day 3 - CMM Day 4 - CReC Day 5 - PACS Day 6 - Long-Acting Injectables Day 7 - CPC Day 8 - HEOR Certificate Day 9 - CCRP Day 10 - CCPC Day 11 - Substances of Abuse Day 12 --- Support this podcast: https://anchor.fm/theedutainer/support
Farah Husein, Director, Evidence Generation, Canadian Centre of Excellence, at Takeda, discusses all things evidence generation, including the impact of the COVID-19 pandemic on HEOR, RWE, epidemiology, and PRO studies and where digital technologies will fit into these types of studies in the future.Schedule a meeting with Natalie Yeadon: https://www.meetwithnatalie.comNatalie Yeadon LinkedIn: https://www.linkedin.com/in/natalieyeadon/Impetus Digital Website: https://www.impetusdigital.com/Impetus Digital LinkedIn: https://www.linkedin.com/company/impetus-digital/Impetus Digital Twitter: https://twitter.com/ImpetusadboardsImpetus YouTube: https://www.youtube.com/ImpetushealthcareFarah Husein: https://www.linkedin.com/in/farah-husein-0507b131/Takeda: https://www.takeda.com/en-ca
The entirety of the US healthcare system was reformed with the advent of Obamacare in 2009 – and we're still feeling the aftershocks over a decade later.So says Keith Kelly, Senior Managing Director, Value, Access and HEOR at Syneos Health Consulting, who returns to the Syneos Health Podcast to continue the discussion on the trajectory of payer influence in the healthcare marketplace. Listen to our previous episodes in the series, Payer Power and Payer Power, Part 2, to get the full story. And for additional market access-focused content, check out these recent publications:The Great Benefits Migration of 2020Demonstrating Value in the Real WorldNon-Personal Promotion: What Do Payers Want?If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.
In this second podcast on the EUMDR, panelists John Pracyk, MD, PhD, MBA, Worldwide Integrated Leader, Medical Affairs, Pre-Clinical & Clinical Research, DePuy Synthes - Spine | Johnson & Johnson Medical Devices Companies welcomes Philip Desjardins, JD, Vice President, Global Regulatory Affairs Spine and Medical Device Regulatory Policy, DePuy Synthes | Johnson & Johnson Medical Devices Companies, and Drilon Saliu, PharmD, MBA, Head, Medical, Clinical and HEOR, Connected Care, Philips, continue their comprehensive discussion of: Covid's impact on EUMDR; USFDA and EUMDR global regulator comparison; short and long term impacts; how Brexit might impact the UK's regulatory oversight; the importance of investing in top talent; new capabilities that are required; the importance of leading with influence; and, evidentiary compliance planning and budget impact.
Host John Pracyk, MD, PhD, MBA, Worldwide Integrated Leader, Medical Affairs, Pre-Clinical & Clinical Research, DePuy Synthes - Spine | Johnson & Johnson Medical Devices Companies welcomes Philip Desjardins, JD, Vice President, Global Regulatory Affairs Spine and Medical Device Regulatory Policy, DePuy Synthes | Johnson & Johnson Medical Devices Companies, and Drilon Saliu, PharmD, MBA, Head, Medical, Clinical and HEOR, Connected Care, Philips, to share insights into the importance of compliance with the new European Device Medical Regulation (EUMDR), including key deadlines for compliance.
Radical changes in the interface of health are rapidly changing where people find care. Where is that, exactly? Quick answer: everywhere. The point of care has been steadily shifting away from where the clinic exists to wherever the patient goes. Advances in digital care connections and the growth of new customer segments have opened up entirely new ways to make healthcare more scalable and accommodating to both baby boomer demands and millennial disruption.A.J. Triano, Senior Vice President, Engagement Strategy at GSW Advertising and Aaron Davis, Managing Director, Value, Access and HEOR at Syneos Health Consulting, discuss the factors impacting this shift, what the new ecosystem is looking like, and what it all means for developers, health care providers, and patients in the longer term. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.
HEOR - HECON - heard these acronyms before? I have - a million times! And I'm so glad that Dr. Erin Zagadailov reached out to The Edutainer and her kind offer to break down this career path for us - with bonus footage - on beekeeping! Erin is Director of Health Economics & Outcomes Research for Rare Disease at a small commercial stage biotech company. Here, she breaks down her own career path within HEOR and shares with us where to learn more about this fascinating area of pharmacy practice within the pharmaceutical industry - AND one with JOB OPENINGS right now! She also mentions ISPOR here too: https://www.ispor.org/ You can connect with Erin at LinkedIn: https://www.linkedin.com/in/erin-zagadailov/ Erin - thank you for busting through and breaking down yet another industry acronym!
Penton and Morezi episode are deep in Heor’s lair. What’s up with those dolls? Who is the mysterious figure in black and what oh WHAT is up with the chicken hut??? Subscribe to us on ITunes and get a new episode every other Monday! Our YouTube channel can be found here: https://www.youtube.com/channel/UCVp7JOI4jLSCSN5JYh3eUkA
On why HEOR and not Public Health as most MDs here do, here's what Dr. Shah had to say about that:“India is a developing country and it is an unmanaged market meaning that most people are still paying out-of-pocket for healthcare. As 70% of India is still rural, access to healthcare in big cities is pretty great but abysmal in villages. And with this poor access, we also don't have access to a lot of life-changing medications. So we can read about the Humiras and Solvaldis (med for treating Hep-C) of the world in the literature, online, and in all these advertisements, but we don't really get access to that for treating our patients. And that is the sort of the frustration of practicing medicine in India, it is not being able to access that. And so, as rewarding as medical school was for me, that point always stuck as to why a population of over 1.5 billion people are not a target for these advanced pharmaceuticals.The more I read about it and the more I educated myself, I learned that the story of healthcare, by the decision makers, was told in terms on US dollars and not on how many lives saved or societal impact. I was purely a dollar conversation. As not really one to changing the system from the outside, I decided to educated myself to change the system from the inside and thus began my journey to learn about health economics.”“I will consider my life a success if I enable access to like two or three life-changing drugs to a couple million patients (in India). I will consider my work done.”
Solai Valliappan previews her talk at the upcoming Young Actuaries Conference (YAC) including the importance of a 'strong network' and how she came to consult on 'the Google Maps of asteroid resources in space'. Angela Poon (Actuarial Consultant at Finity Consulting) asks Solai Valliappan (Business Advisor at HEOR) how she attained her current role and how she has become an advisor to multiple actuarial facets of businesses from risk management to strategy to data analytics and finance.Solai's experience is varied as she enjoys working on multiple projects and utilising her actuarial skills to help businesses in non-traditional fields excel.Angela asks a range of questions including:- How do you get to be an advisor in areas of finance, data analytics, strategy and risk management all in one time?- How has a strong network helped you in your career?- Do you have any tips or advice for people who are trying to explore or venture into a non-traditional field?- How did you find your passion with working in the space area?- Can you tell our listeners what sort of things can they expect to get out of the upcoming Young Actuaries Conference?Download the Transcript herehttps://actuaries.asn.au/Library/Miscellaneous/2018/ActuariesYACTranscript.pdfFollow the Actuaries Institute across all social;↳ Facebook: https://www.facebook.com/pages/Actuaries-Institute/183337668450632↳ Instagram: https://www.instagram.com/ActuariesInst↳ Twitter: https://www.twitter.com/ActuariesInst↳ LinkedIn: https://www.linkedin.com/company/792645/↳ Spreaker: https://www.spreaker.com/user/actinst↳ YouTube: https://www.youtube.com/subscription_center?add_user=ActuariesInstituteCPD members can earn 2 points for each Podcast listened to.
Solai Valliappan previews her talk at the upcoming Young Actuaries Conference (YAC) including the importance of a 'strong network' and how she came to consult on 'the Google Maps of asteroid resources in space'. Angela Poon (Actuarial Consultant at Finity Consulting) asks Solai Valliappan (Business Advisor at HEOR) how she attained her current role and how she has become an advisor to multiple actuarial facets of businesses from risk management to strategy to data analytics and finance.Solai's experience is varied as she enjoys working on multiple projects and utilising her actuarial skills to help businesses in non-traditional fields excel.Angela asks a range of questions including:- How do you get to be an advisor in areas of finance, data analytics, strategy and risk management all in one time?- How has a strong network helped you in your career?- Do you have any tips or advice for people who are trying to explore or venture into a non-traditional field?- How did you find your passion with working in the space area?- Can you tell our listeners what sort of things can they expect to get out of the upcoming Young Actuaries Conference?Download the Transcript herehttps://actuaries.asn.au/Library/Miscellaneous/2018/ActuariesYACTranscript.pdfFollow the Actuaries Institute across all social;↳ Facebook: https://www.facebook.com/pages/Actuaries-Institute/183337668450632↳ Instagram: https://www.instagram.com/ActuariesInst↳ Twitter: https://www.twitter.com/ActuariesInst↳ LinkedIn: https://www.linkedin.com/company/792645/↳ Spreaker: https://www.spreaker.com/user/actinst↳ YouTube: https://www.youtube.com/subscription_center?add_user=ActuariesInstituteCPD members can earn 2 points for each Podcast listened to.
Clinical Trial Podcast | Conversations with Clinical Research Experts
“Don’t be afraid to try new things” - James Hasegawa This is a special episode in Health Economics and Outcomes Research (HEOR) with James Hasegawa. James is a director at Abbott and is responsible for HEOR projects. In this episode, James shares insights on how healthcare reimbursement works as it related to clinical trials. We also dig into the world of Health Technology Assessment (HTA) groups and what it takes to model reimbursement for a medical product. If you’re interested in breaking from the silos of clinical research and learn about important adjacent functions such as HEOR, this episode is for you. Do you have a topic idea for my next podcast episode? If so, leave me your suggestion is the comments section below. Listen to it on iTunes.Stream by clicking here.Download as an MP3 by right-clicking here and choosing “save as.” Selected Links from the Episode Connect with James LinkedIn Medicare International Society for Pharmacoeconomics and Outcomes Research (IPSOR) BIO conference Stanford Biodesign Program Centre for Health Economics at University of York The National Institute for Health and Care Excellence (NICE) What is a MAC? Hospital Readmissions Reduction Program Books Mentioned: Leading at Mach 2 by Steve Sullivan Good to Great by Jim Collins The Tipping Point: How Little Things Can Make a Big Difference by Malcolm Gladwell Biodesign: The Process of Innovating Medical Technologies by Paul G. Yock and Stefanos Zenios Methods for the Economic Evaluation of Health Care Programmes (Oxford Medical Publications) by Michael F. Drummond, Mark J. Sculpher, Karl Claxton, Greg L. Stoddart, George W. Torrance Show Notes: What is Health Economics [01:52] James’s personal story: career path to HEOR [06:09] Daily routine of HEOR professionals [13:26] NICE and other HTA [14:30] HTA in the United States [15:15] HTA vs. MAC [16:30] The future of HEOR [18:59] Hospital Readmissions Reduction Program (HRRP) [19:58] Economic value and what should a medical product start-up do? [24:17] How to find HEOR consultants [25:00] Qualities of HEOR people [28:06] Health economic model: how to make one? [28:57] Working with Medicare Administrative Contractor (MAC) [31:38] The future of HEOR (continued) [33:20] On Big Data [34:57] Leveraging HEOR data in countries such as US and Japan [36:52] How does HTA function in the US [38:26] Resources and guidance documents on HTAs [40:23] HTA review process in Japan [43:30] Trick to learning other therapeutic areas [47:55] What was most useful for you in this episode? Leave me a comment below and thanks for listening.
© 2020-2025 Ivy Podcast Discovery LLC
